A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031

NCT00814736 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Hyperplasia
Urinary Bladder, Overactive
Erectile Dysfunction

Interventions

DRUG: UK369,003
DRUG: sildenafil
DRUG: sildenafil matching placebo

Sponsor

Pfizer